Introduction
According to the most recent study of the global burden of disease, diarrheal diseases were responsible for almost 1.3 million deaths worldwide in 2013, and intestinal infectious diseases were responsible for another 221,300 deaths. 1 The pathogens responsible for deaths from diarrhea vary between regions; Clostridium difficile is a leading pathogen in high-income countries, whereas Shigella and Aeromonas infections are more common in areas where levels of sanitation are poor. 1 The burden of diarrheal diseases, like many other conditions around the world, is not randomly distributed but is disproportionately borne by the most vulnerable-the poorest of the poor, the very young, the very old, and females. 2 The Asia-Pacific region is politically, economically, and culturally diverse, encompassing high-income, middle-income, and lowincome countries in both hemispheres, and including more than half of the world's population. Rapid economic growth has led to reduced mortality and increasing affluence, with accompanying adoption of Western diets, reduced physical activity, a growing rate of obesity and chronic disease, and an aging population. 3 As a result, there have been epidemiological shifts in the profile of gastrointestinal disease, with an increase in gastroesophageal reflux disease and inflammatory bowel disease (IBD), 3 and a reduction in rates of infectious diarrhea. 1 However, infectious diseases including Helicobacter pylori infection and infectious diarrhea still predominate over gastroesophageal reflux disease and IBD in Asia as a whole compared with Western countries.
There is increasing evidence that the gut microbiota is "an integral component of human physiology," 4 with an important role in shaping immune responses. 5 As a result, changes in the microbiota can contribute to a range of immune, inflammatory, and metabolic disorders. 4 This has also led to research into the impact of "probiotics"-strains of bacteria that may beneficially impact intestinal function-on human health and disease through their modulation of the human gut microbiota. 6 Internationally, several organizations, such as the World Gastroenterology Organization, have reviewed the evidence and developed recommendations on the use of probiotics for the prevention and treatment of disease. [6] [7] [8] [9] However, to date, no group has specifically considered data relevant to the Asia-Pacific region. Consensus guidelines on the use of probiotics may assist healthcare professionals in the management of gastrointestinal diseases, especially, given the growing amount of literature on the subject and the increasing number of available probiotic strains, with many having limited clinical evidence.
In order to address this subject, a meeting of 14 international experts from leading Asia-Pacific countries was held at the Sorbonne University, Paris, France, on April 11 and 12, 2016 , to discuss current evidence supporting the use of probiotics for the management of gastrointestinal disorders in the region. This was the first AsiaPacific Probiotics Consensus Meeting. The principal goal of the meeting was to review available data on the role of the gut microbiota and probiotics in digestive diseases in the Asia-Pacific region and, based on this review, to define specific objectives for an expert panel whose aim would be, for the Asia-Pacific region, to develop recommendations on the use of probiotics, propose topics for future research on the topic and give direction on the approach to the regulation of probiotics in the region.
Methods
The 1st Asia-Pacific Probiotics Consensus Meeting in Paris included experts from Australia, China, India, Indonesia, Japan, South Korea, and Singapore, as well as outside Asia-Pacific (USA, Uruguay, UK, The Netherlands, and Italy). The meeting included discussions on the epidemiology of diarrheal diseases in Asia-Pacific, the use of probiotics in the region, and regulations relating to probiotic use, as well a more general review of current evidence supporting their use in the management of gastrointestinal disorders. Workshops on the use of probiotics in both adults and children were held; this article describes the status of research on probiotic use in adults. A separate article summarizes the outcomes of the discussion on the use of probiotics in children. Principal considerations in the development of these consensus recommendations were the epidemiology and etiology of diarrheal and other gastrointestinal diseases in the Asia-Pacific region, the evidence from the region and internationally to support the use of probiotics for adult gastrointestinal conditions, and issues pertaining to probiotic formulation, availability, affordability, and quality, as well as the regulatory environment. This article provides an overview of consensus-based outcomes from guideline-development discussions held by the expert panel at the Paris meeting and the consensus reached, at a meeting subsequently held in Kobe, Japan, on the proposed recommendations, using the Likert scale. 10 
Findings/recommendations
Review of relevant background literature. Based on a detailed survey of the available literature and its review by the panel of experts, the following topics were defined as relevant to a consideration of the use of probiotics in the region:
• The gut microbiota, a general overview • Potential indications for probiotic use:
• Infectious diarrhea in the Asia Pacific region, given that infectious diarrhea is one of the most common indications for probiotic use worldwide, • Helicobacter pylori • Other diarrheal diseases • Overview of probiotics, in general-probiotics-what are they? • Probiotics in the management of gastrointestinal disorders:
The gut microbiota. It has been estimated that the average person contains about 10 14 microorganisms, collectively weighing more than 1 kg. 11 In the intestine, bacteria are most abundant in the colon, and least abundant in the proximal duodenum. 4 More than 2000 species of commensal bacteria make up the gut microbiota, 4 but anaerobic phyla (principally Bacteroidetes and Firmicutes) predominate. 12 In addition, there is evidence of significant differences in the microbiota in relation to age, geographic location, ethnic and socioeconomic background, and dietary pattern.
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It is difficult to define a truly "healthy microbiota" currently as there are considerable inter-individual and regional variations in gut microbiota. However, we do know that the gut microbiota performs several important metabolic functions (vitamin synthesis, bile salt metabolism, and xenobiotic metabolism), as well as influencing epithelial cell turnover, mucosal homeostasis, barrier function, and immune signaling. 4 The abundance of certain species does not necessarily reflect their functional importance to the host, because some species present in low numbers perform essential, specialized functions. 12 Therefore, the definition of a normal microbiota probably needs to reflect a balance, not simply between species or genera but between the relative enzymatic activity or metabolic functions of the species present. 6 Further complicating the definition of a normal microbiota is that different types of bacteria colonize the lumen and mucosa, but fecal sampling disproportionately yields luminal species. 13 Just as there is no established definition of a normal microbiota, characterizing an abnormal microbiota, an imbalance in gut flora, (oftentimes referred to as "dysbiosis" in the literature), remains challenging.
14 What has been established, however, is that certain disease states are associated with particular microbial profiles and that changes in the microbiota may contribute to certain disease states such as IBD, obesity, type 2 diabetes, non-alcoholic steatohepatitis, and atherosclerosis, as well as gastrointestinal and prostate cancers. [15] [16] [17] In murine models, obese mice had a distinctly different microbial profile than lean mice. 18, 19 Moreover, transferring microorganisms from the gut of obese mice to lean mice, and vice versa, affected the way the microorganisms metabolized food, thereby reversing or inducing obesity, respectively. 18 High-fat foods are metabolized by certain bacteria, and the byproducts of bacterial metabolism (e.g., choline and trimethylamine N-oxide) have been implicated in the development of atherosclerosis and liver disease. 16, 20 Antibiotic therapy can alter the profile of commensal bacteria, 21 with effects on the microbiota still apparent as late as 2 years after the antibiotic course. 21 This may explain the significantly increased risk of IBD in subjects who have received antibiotics in the previous 2 to 5 years, and the risk increases with the number of times antibiotics have been prescribed. 21 Furthermore, an association between microbiota perturbation caused by antibiotic exposure and an increased risk of developing obesity has been suggested. 22 Potential indications for the use of probiotics in the Asia-Pacific region Diarrheal diseases in adults in the Asia-Pacific region. It is difficult to estimate the incidence of diarrhea in Asia-Pacific because of variability in reporting. The self-reported prevalence of diarrhea in adults was 6.4% in a nationwide sample in Australia 23 and 17.5% in Beijing, China. 24 Lamberti and colleagues used published data to estimate the incidence of diarrhea, and diarrhea-related deaths in South and South-East Asia, excluding hospital-associated or antibiotic-associated cases. 25 According to this estimate, diarrhea occurred at a median rate of 30 per 100 people-years in those aged ≥ 15 years. This equates to approximately 385 million episodes of diarrhea in the region per year. 25 A median of 3.7% of deaths in people aged ≥ 15 years could be attributed to diarrhea.
In Malaysia, the nationwide incidence of diarrhea over a 4-week period was estimated to be 5% and was highest (7.3%) in adults aged 20 to 29 years. 26 A similar monthly prevalence of diarrhea (8.5%) was reported in the northwestern Gansu province of China, a less economically advanced area than other parts of China. 27 This translates to an annual incidence of 1.16 episodes per person-year, 27 which is around four times higher than the estimated annual incidence in adults in rural Vietnam (0.28 episodes per person-years at risk). 28 Risk factors for diarrhea include younger age (15-24 years), 28 indicators of poverty (living in a rented house, lower education levels, shared access to drinking water, and low monthly income), 26, 29, 30 living in a rural area, 26 living close to a hospital, 29, 30 exposure to waste water or excreta during work, 29 and poor hand/food hygiene practices.
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Infectious diarrhea. Much of the recent data on causative pathogens in infectious diarrhea in Asia-Pacific originate from China, and the Indian subcontinent (Table 1) . [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] Aside from a very high prevalence of Cryptosporidium (55% of stool samples from diarrhea patients) in Karachi, Pakistan, 31 parasites and protozoa were generally less common causes of diarrhea than viruses or bacteria. 36, 38, 43 The most common causative viruses are norovirus and rotavirus, 34, 38, 40, 42 and the most common causative bacteria are enterotoxigenic Escherichia coli, Vibrio cholerae, Vibrio parahaemolyticus, and Shigella spp. [33] [34] [35] [37] [38] [39] 41 Salmonella spp. were a rare cause of infectious diarrhea in these studies, causing fewer than 2% of cases. 34, 37, 38 In the urban slums of Kolkata, cholera occurs at an annual rate of 0.90 per 1000 people aged ≥ 15 years per year, and the annual incidence of V. parahaemolyticus diarrhea is 0.63 per 1000 per year in this age group. 30 V. parahaemolyticus is also a common cause of diarrhea among Chinese outpatients, responsible for 6% of diarrhea cases in one analysis in Shenzhen City, 93% of whom were young adults (15 to 39 years). 39 Infections peak in summer (June through October), when V. parahaemolyticus is responsible for 30% of outpatient infectious diarrhea cases. 39 In North Jakarta, Indonesia, the highest number of diarrhea cases occurred during the rainy season (January-April) with significant numbers caused by V. parahaemolyticus.
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Antibiotic-associated diarrhea. There are limited data on the incidence of antibiotic-associated diarrhea (AAD) among outpatients in Asia-Pacific, but data from China suggest that approximately 1% of hospitalized patients develop AAD. 45 Among reports of AAD cases in Asia, C. difficile is implicated as the causative organism in 23% of cases in Korea, 46 and in 30.6% of cases in China. 45 Based on stool samples from hospitalized patients with diarrhea, C. difficile is responsible for between 13.7% (Malaysia) and 34.6% (China) of hospital-acquired diarrhea in Asia, [46] [47] [48] [49] or between 0.45 cases per 1000 patient-days (Taiwan) and 4.8 cases per 1000 patient-days (Bangladesh). 50, 51 Risk factors for C. difficile infection reported in a recent Korean study were older age (> 66 years), female sex, number of antibiotics used, use of proton pump inhibitors, use of cephalosporins, underlying cancer, and cerebrovascular disease. 52 It is important to note that while rates of C. difficile-related diarrhea are on the rise in Asia, rates still remain lower than in the US and Europe. 53, 54 Furthermore, available data indicates that the most prevalent strains, as identified through genotyping, are quite different in Asia from those commonly isolated in North America and Europe. [53] [54] [55] [56] [57] [58] For example, the hypervirulent 027 strain, so problematic in North America, 53 has only recently been reported and then rarely, in Asia. 59, 60 One interesting epidemiological note, zoonotic transmission of C. difficile from pigs to man has been reported in Taiwan. 61, 62 Travelers' diarrhea. Travelers' diarrhea (TD) is common among visitors to South-East Asia. One Thai survey among foreign tourists found that around 30% had experienced diarrhea during their travels in South-East Asia, 63 and a Dutch study estimated that 50% of travelers to developing countries experienced at least one episode of diarrhea. 64 Asia, particularly the Indian subcontinent, is a common destination among European travelers who report diarrhea on their return home. [64] [65] [66] TD occurs among European people visiting the Indian subcontinent at a reported 2-week incidence of 26.3%, 65 or an incidence rate of 3.83 per 100 travel-days. 67 In a survey in Guangdong, China, 11.6% returning travelers had experienced diarrhea. The incidence was 15.3% for those who visited South-East Asia and 5.6% for other destination; 13.3% for those from economically developed areas and 8.1% for those from developing areas. 67 In travelers to Asia, the most common causative organisms are E. coli (enterotoxigenic or enteroaggregative forms), norovirus, Campylobacter spp., and V. parahaemolyticus. Gut microbiome/probiotics in Asia-Pacific UC Ghoshal et al.
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Parasites or protozoa are uncommon causes of TD, 66, 72 but most travelers to Asia who acquire protozoan infections do so in India. 72, 73 Helicobacter pylori. Helicobacter pylori infection is known to cause a range of gastrointestinal disorders, including peptic ulcers, gastric cancer, gastric lymphoma, and H. pylori gastritis, which is now considered as an infectious disease. 74 H. pylori is a heterogeneous bacterium, with particular virulence factors that confer greater morbidity, 75 which helps to explain some of the geographical discrepancies between gastric cancer rates relative to H. pylori carriage rates, such as the high rate of gastric cancer in Japan relative to India. 3, 76 Asian countries have some of the highest rates of H. pylori infection in the world, but the prevalence varies considerably across the region. 76 The lowest rates of infection have been reported in the islands of the Indonesian archipelago, 77, 78 and the highest rates in India, 79 Japan, and South Korea. 76 The weighted mean prevalence of H. pylori infection in China was estimated to be 55-56%, 80, 81 but rates as high as 83.4% have been reported in the elderly population of Beijing 82 and 84.6% in Tibet. 81 Analyses of time trends have shown a decrease in the prevalence of H. pylori infection over time in a number of Asia-Pacific countries, including China and Japan, with a recent study reporting a prevalence of 30-40% in Japan, which no longer classifies it as a country of high prevalence. 3, 75, 76, 80, 83, 84 Improvements in standard of living and hygiene practices have influenced the observed decrease in H. pylori prevalence 76, 80 ; by reducing exposure to infants and children, a cohort effect has contributed to these time trends in some countries. 76 In Japan, these changes likely also reflect the Japanese government's efforts to screen for and treat H. pylori as part of a nationwide strategy to reduce the gastric cancer rate. 85 Other diarrheal diseases. Other diarrheal diseases that occur in Asia include the diarrhea-predominant form of irritable bowel syndrome (IBS), IBD, celiac disease, and lactose intolerance.
The reported prevalence of IBS is 4.4% in Taiwan, 86 5-6% in China, 87 10.9% among ethnic Malays in Malaysia, 88 and 13.5% in Japan. 89 A similar prevalence of IBS among ethnic Chinese, Indians, and Malays living in the same community has also been demonstrated, 90 and two studies conducted in Indian rural communities reported a 4-6.8% prevalence of IBS. 91, 92 Diarrhea is a common symptom of IBS in Asia, with most IBS patients in China having the diarrhea-predominant subtype. 93 IBS may develop after an episode of infectious diarrhea 94 and has been associated with lactose intolerance and small intestinal bacterial overgrowth. 95 Although IBD tends to be less common in Asia than in Europe or North America, the general prevalence of IBD, particularly ulcerative colitis (UC), is increasing in the Asia-Pacific region. 3, 96, 97 Based on epidemiological data, the urbanization of rural areas is closely linked with the increasing incidence of IBD in Asia. 98 IBD prevalence is particularly high in India and Japan, and people of South Asian ethnicity (Indians, Pakistanis, and Bangladeshis) have a genetic predisposition to the development of UC. 96 Unlike elsewhere in the world, there is a poor association between mutations in the NOD2/CARD15 gene and Crohn's disease in Asian populations, 96, 97 suggesting that there is a different pattern of genetic predisposition to this disease in the Asia-Pacific region. The clinical phenotypes of Asian patients with IBD are generally similar to those in Western populations, 97 with males predominating over females in Crohn's disease. 96 Lactose malabsorption is highly prevalent in Asia, affecting between 70% and 100% of populations. [99] [100] [101] In India, the prevalence shows a North-South geographic variation, with a higher prevalence in southern states. 99 Lactose malabsorption occurs because of the genetically programmed decline in intestinal levels of the lactase-phlorizin hydrolase enzyme over time, such that lactase-phlorizin hydrolase levels become negligible by adulthood. 100 Patients with lactose malabsorption develop a range of gastrointestinal symptoms, including diarrhea and cramping, after consuming lactose-containing foods. 101 Probiotics-What are they? As knowledge about the microbiome in health and disease has expanded, so has interest in therapeutic manipulation of the microbiome. One such approach is the administration of probiotics. Probiotics were defined in 2002 as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host." 102 However, this definition has been criticized because the microbiota, at least in the laboratory, may also respond to dead organisms or to bioactive molecules produced by bacteria, including proteins, peptides, nucleotides, or polysaccharides. 103 The term may encompass probiotics in food, as well as those administered as a supplement or medicine. An alternative term, pharmabiotic, has been proposed to specifically denote "any biological entity mined from or influencing the microbiota with potential therapeutic benefit." 103 Humans have been consuming probiotics for centuries in fermented foods, but commercial production began in 1906 with the development of fermented milk products. 104 Interest in the potential health effects of food containing microorganisms grew throughout the 20th century. In the 1960s, the term probiotic began to be used to describe microorganisms that produce lactic acid. 104 Probiotic microorganisms should present the following characteristics: no pathogenic effects to humans, be able to survive transit through the acid environment of the stomach, bile, and enzymes in the small intestine, be capable of colonizing the intestinal mucosa, reduce pathogen adherence to surfaces, and show antimicrobial activity against pathogenic bacteria. 105 Once there, they exert beneficial effects via a number of mechanisms, including effects on intestinal barrier function, interactions with intestinal immune cells to alter the local inflammatory environment, and directly or indirectly modulating the existing microbiota. 6 They may directly attack pathogenic gut bacteria by producing bacteriocins, or they may indirectly affect their survival and growth via changes to the gut microenvironment and/or competition for nutrients. 6 The biological properties of a range of putative probiotic organisms have been extensively studied in vitro and in animal models and a host of effects of potential impact in human disease identified; these have been extensively reviewed elsewhere and will not be discussed further in this review. 6, 20, 103, 105, 106 The most common probiotic bacterial strains available for use in adults are Lactobacillus spp., Bifidobacterium spp., E. coli Nissle, and Streptococcus thermophilus, and the yeast Saccharomyces boulardii (Table 2) . 107, 108 Probiotics are available in a wide variety of formats: as single organisms, as a cocktail of multiple organisms, or in combination with a prebiotic (referred to as a synbiotic). Although undoubtedly exerting important biological and clinical effects, a further discussion of prebiotics and, thus, synbiotics is beyond the scope of this review. Probiotics generally have an excellent and long-standing safety record but are not entirely without risk. 6, 109 The risk of developing adverse events may be increased in particular patient groups, such as premature infants, immunocompromised individuals, critically ill patients (e.g., those with acute pancreatitis), and those with central venous catheters. 6, 109 In these patients, probiotics have occasionally been associated with the development of potentially serious infections. 6, 109 One of the problems in determining the safety profile of probiotics is that these agents are often grouped together as a single entity, when they should be considered on a strain-by-strain basis. 103 There are also limited published data specifically addressing the safety of individual probiotics. 109 Therefore, more data examining the long-term safety of each individual probiotic strain are needed, including their potential as a reservoir for antibiotic resistance genes. 109 Probiotics in the management of gastrointestinal disorders. The World Gastroenterology Organization developed global guidelines for the use of probiotics and prebiotics in adults and children in 2011. 9 They determined that there was good evidence from randomized controlled trials (evidence level 1b) or from meta-analyses of randomized trials (level 1a) to support the use of probiotics in a number of adult indications (Table 3) .
Since publication of these guidelines, several further metaanalyses have been conducted into the use of probiotics for gastrointestinal diseases.
Antibiotic-associated diarrhea. Otherwise, unexplained diarrhea that occurs in association with antibiotic treatment is classified as AAD. 110 The use of probiotics, which are thought to ameliorate the disruptive effects of antibiotics on the microbiome, may provide a method for prevention and treatment of AAD and C. difficile-associated diarrhea. 111 A Cochrane systematic review found that probiotics significantly reduced the risk of C. difficile-associated diarrhea in adults and children and may have reduced the risk of adverse events during treatment but had no effect on the overall incidence of C. difficile infection or on the duration of hospital stay. 111 In contrast, a separate meta-analysis by Pattani and colleagues found that probiotics significantly reduced the risk of C. difficile infection, with a number needed to treat (NNT) of 14. 112 Furthermore, in a meta-analysis by McFarland and colleagues, the use of probiotics was associated with significant improvements in the primary prevention of C. difficile infections, but there was no significant difference in secondary prevention with probiotic use. 113 Probiotics also reduced the risk of AAD in adults in the Cochrane analysis, 111 and the meta-analysis by Pattani and colleagues (NNT of 11 for this outcome), 112 but may not have been as effective in elderly patients (age ≥ 65 years). Chinese researchers conducted a meta-analysis of six randomized trials and found no evidence that probiotics significantly reduced the risk of AAD in the elderly age group. 114 It should be noted that the evaluation of the use of probiotics in the prevention of C. difficile infection has been largely restricted to its assessment as a secondary outcome of studies in AAD. 114 Moreover, meta-analyses supporting the use of probiotics for the prevention of AAD in adults and children are often restricted by their limited assessment of different probiotic strains. [111] [112] [113] [114] Szajewska and colleagues have conducted meta-analyses of data specifically relating to Lactobacillus rhamnosus GG 115 and S. boulardii 116 and found that each of these probiotics significantly reduced the risk of AAD in adults and children. However, the quality of evidence was graded moderate to low for both probiotics using the Grading of Recommendations, Assessment, Development, and Evaluation methodology.
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Irritable bowel syndrome. There is some recent level 1a evidence to support the use of probiotics for pants with IBS. Ford and colleagues conducted a meta-analysis of 35 placebo-controlled trials of probiotics in adults with IBS involving 3452 patients. 117 They found that probiotics had a significantly favorable effect on a range of outcomes, including persistent symptom relief, abdominal pain or global symptoms, bloating, and flatulence (Table 4) . The NNT for symptom improvement was 7. More studies were available for combination probiotic formulations than for individual strains, and these combinations significantly reduced all outcomes. Of the individual probiotics assessed, Lactobacillus strains significantly improved flatulence, Bifidobacterium improved abdominal or global symptom scores, and Escherichia and Streptococcus strains both provided persistent symptom relief. 117 Chinese researchers conducted a meta-analysis of six randomized trials, including three trials of adult patients from India, South Korea, and China who received Lactobacillus-containing probiotics, and found that treatment for 4 to 8 weeks significantly increased the odds of clinical improvement in adults with IBS (relative risk [RR] vs placebo of 17.62 [95% CI 5.12-60.65]; P < 0.00001). 118 Despite the positive results, there was significant heterogeneity between studies in this analysis, and the authors recommend more research in larger studies. 118 A randomized, placebo-controlled cross-over trial in Japan found that 4 weeks of treatment with Lactobacillus brevis KB290 was significantly more effective than placebo for improving quality of life, and reducing the frequency of watery stools and abdominal pain, but did not significantly affect overall IBS symptom scores. 119 Stool samples collected at the end of treatment with L. brevis contained significantly higher amounts of Bifidobacterium spp. and lower amounts of C. difficile compared with the placebo period, but other bacterial counts were unaffected. 119 In a randomized clinical trial of patients with IBS, S. boulardii was associated with significant improvements in health-related quality of life compared with placebo; however, it did not improve individual intestinal symptoms. 120 Finally, several studies conducted in Korea found that probiotics altered the microbiota and exerted therapeutic benefits for patients with IBS. [121] [122] [123] [124] Inflammatory bowel disease. The data on the use of probiotics in IBD are still relatively limited. One meta-analysis found that VSL #3 (a mixture of S. thermophilus, Lactobacillus, and Bifidobacterium strains) was effective for inducing remission in patients with active UC (RR 1.69 [95% CI 1.17-2.43]) compared with placebo (data from three studies). 125 This analysis included data from a double-blind, placebo-controlled study conducted in India, in which VSL #3 proved to be more effective than placebo for relieving symptoms and inducing remission in adults with mild-to-moderate UC. 126 However, the meta-analysis found that Bifido-fermented milk was not statistically superior to placebo or no treatment for inducing remission in active UC based on two studies (RR 2.70 [95% CI 0.47-15.33]). 125 VSL #3 was also significantly more effective than placebo for preventing relapses in patients with UC or ileo-anal pouch anastomosis (RR 0.17 [95% CI 0.09-0.33] from three studies), but E. coli Nissle 913 was not effective for preventing relapses in UC (RR 1.08 [95% CI 0.86-1.37]; three studies). Neither L. rhamnosus GG nor Lactobacillus johnsonii was more effective than placebo for preventing relapses in Crohn's disease (based on two studies each). 125 Travelers' diarrhea. Probiotics may also be used in the prevention of TD. In a meta-analysis by McFarland and colleagues, several probiotics (including S. boulardii and Lactobacillus strains) were associated with significant improvements in the prevention of TD compared with placebo (RR Helicobacter pylori infection. According to the fourth edition of the Maastricht consensus report on the management of H. pylori infection, adjuvant treatment with certain probiotics may reduce the incidence of adverse effects during treatment.
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Two meta-analyses conducted by Chinese researchers have found that probiotics generally, 128 and Lactobacillus-containing probiotics specifically, 129 significantly enhance H. pylori eradication rates when administered with eradication therapy (Table 5) . Lactobacillus-containing probiotics were effective in adults, as well as children. 129 The improved eradication rates could be due to a better tolerability of the antibiotic combination therapies and, therefore, better compliance. Furthermore, when the analysis was limited to multi-strain probiotics, the difference versus placebo was no longer significant. 128 In the meta-analysis of Zhang and colleagues, the use of adjunctive probiotics also reduced the incidence of adverse events associated with eradication therapy by 41% (RR 0.59 [95% CI 0.48-0.71]; P < 0.001). 128 However, the meta-analysis of specifically Lactobacillus-containing probiotic use found that these agents did not reduce the incidence of adverse effects (RR 0.88 [95% CI 0.73-1.06]; P = 0.19). 
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Other indications. There are several other potential indications for probiotic use and include lactose intolerance, post-infectious IBS, tropical sprue, small intestinal bacterial overgrowth (e.g., after prolonged use of proton pump inhibitors), non-alcoholic fatty liver disease, complications of liver disease, constipation, and enteropathy associated with non-steroidal anti-inflammatory drugs. Probiotics are also being actively investigated in a range of indications aside from those affecting the gastrointestinal tract, including respiratory tract infections, urinary tract infections, bacterial vaginosis, pollenosis, allergic rhinitis and asthma, diabetes mellitus, hyperlipidemia, obesity/metabolic syndrome, and minimal hepatic encephalopathy. However, there is currently insufficient evidence supporting a recommendation for probiotics in these indications.
Importance of regional guidelines. Guidelines have an important role in clinical medicine, by helping to crystallize currently available scientific data into an accessible format than can guide rational prescribing decisions in day-to-day practice. Guidelines developed in one country may or may not be applicable in another, depending on the prevalence/etiology of the clinical condition and the availability or cost of recommended interventions. Therefore, it is advisable for guidelines to be developed for individual countries or regions. For any group considering guideline development, there are two options: develop de novo guidelines or adapt or modify existing guidelines based on their applicability to national or regional clinical practice. While de novo guidelines provide reliable standards of practice based on the best available evidence, the process of guideline development is timeconsuming, resource-intensive, and requires expertise. An alternative approach is to modify international guidelines for national or regional use, by assessing how well the international data apply locally in terms of disease epidemiology and etiology, and healthcare environments.
Only a few countries in the Asia-Pacific region have guidelines for the use of probiotics in adult indications, and where probiotics are recommended, conclusions are based largely on international rather than local or regional studies. In Japan, the management guidelines for H. pylori eradication recommend the use of probiotics as adjuvant therapy 131 ; this is in line with the recent conclusions of the Maastricht V process. 74 In Japan, probiotics have also been recommended in the management of IBS. 132 Consensus recommendations. The burden of gastrointestinal disease differs across geographic regions, and between countries within regions such as Asia-Pacific. Therefore, recommendations on the use of probiotics must take these differences into account and also address the quality, safety, strain specificity, and efficacy of probiotics available in the Asia-Pacific region. The objectives of this expert panel will be to Gut microbiome/probiotics in Asia-Pacific UC Ghoshal et al.
• Clearly define what is meant by the term "probiotic" so that consistent terminology can be used among health-care providers and manufacturers and clear information can be provided to patients; • Conduct or coordinate surveillance studies on the currently available forms of probiotics in Asia-Pacific and how these probiotics are prescribed, accessed, and used; • Make recommendations on quality control on the manufacture of probiotics, as well as on those regulatory and labeling directives that will ensure that safe and effective products are available for patients in Asia-Pacific; • Analyze available evidence for the efficacy and safety of probiotics and the applicability of this evidence to the AsiaPacific region; this would include defining regionally important indications and supportive evidence for probiotic efficacy in these indications; • Identify gaps in the research on probiotics in Asia-Pacific and recommend appropriate research strategies to fill these gaps, including the assessment of strain-specific efficacy and comparative efficacy of single strains versus combinations in the region; • Develop evidence-based recommendations for the use of probiotics in Asia-Pacific based on international and local evidence.
The panel of experts met in Kobe, Japan, in November 2016 to vote on the proposed recommendations for the Asia-Pacific region; a summary of the results are presented in Table 6 .
Conclusions. There is growing evidence to support the therapeutic potential of probiotics in modulating gastrointestinal functions and relieving symptoms of gastrointestinal disorders, but more research is needed both in Asia-Pacific regions and internationally. Because the spectrum of diseases seen across Asia-Pacific differs from those in Europe or North America, an Asia-Pacific Probiotics as single therapy are effective in the induction of remission in ulcerative colitis.
Dismissed
Probiotics when combined with a 5-aminosalicylic acid compound increase remission rates in ulcerative colitis.
Agreed
Probiotics as single therapy are effective in the maintenance of remission in ulcerative colitis.
Probiotics when combined with a 5-aminosalicylic acid compound enhance the maintenance of remission in ulcerative colitis.
Crohn's disease Probiotics are effective in the induction of remission in Crohn's disease. 2.2 Dismissed Probiotics are effective in the maintenance of remission in Crohn's disease.
2.2 Dismissed Probiotics are effective in the prevention of recurrence following surgery in Crohn's disease.
Dismissed
Pouchitis Probiotics are effective in the primary prevention of pouchitis. 2.4 Dismissed Probiotics are effective in the prevention of relapse following successful antibiotic therapy of an episode of pouchitis.
Agreed
Irritable bowel syndrome Some probiotics are effective in the relief of symptoms in irritable bowel syndrome.
Probiotics are effective in the prevention of relapse following successful antibiotic therapy of an episode of pouchitis.
Helicobacter pylori infection Concomitant probiotic administration reduces side effects related to antibiotic therapy in adults undergoing eradication therapy for H. pylori. A) Certain strains are more effective than others.
4 Agreed
Concomitant probiotic administration increases eradication rates in adults undergoing eradication therapy for H. pylori. A) Certain strains are more effective than others. Consortium on Gut Microbiota is recommended to define the nature of the Asia-Pacific microbiome and its relationships with health and disease across the region. In addition, an expert panel should be established to provide clear recommendations on the use of probiotics in adults in Asia-Pacific, as well as highlighting important avenues for future research.
